Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Angiogenesis in multiple myeloma: Implications in myeloma therapy|
|Citation:||Cancer Reviews: Asia-Pacific, 2004; 2(2):119-129|
|Publisher:||World Scientific Publishing Co. Pte. Ltd.|
|Sally K Martin, Luen Bik To, Noemi Horvath, Andrew CW Zannettino|
|Abstract:||Angiogenesis, or the formation of new blood vessels from pre-existing vasculature through sprouting or invagination, is a complex process involving many factors. The role of angiogenesis in the progression of cancer has been extensively explored, and it is now well established that elevated levels of angiogenesis in many solid tumors correlates with poor prognosis. Similarly, recent evidence suggests that blood vessel formation plays a pivotal role in the progression of hematological malignancies, including the plasma cell malignancy, multiple myeloma. Several studies have shown that bone marrow angiogenesis is significantly increased in patients with active multiple myeloma and is indicative of poor prognosis. Malignant myeloma cells are known to secrete several angiogenic factors which may play a role in the increased angiogenesis in the bone marrow of myeloma patients. Anti-angiogenic therapy with thalidomide is now considered to be a standard therapy for advanced myeloma patients and a number of new anti-angiogenic therapies are currently undergoing clinical trials for use in this disease.|
|Keywords:||Angiogenesis; Multiple myeloma; Thalidomide; Plasma cell; Therapy; Angiogenic factors|
|Rights:||Copyright status unknown|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.